Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Double Blind Placebo-Controlled Study of BIT225, an Orally Administered SARS-CoV-2 Viroporin Inhibitor, to Evaluate Antiviral Activity, Safety, and Immune Biomarkers in Non-Hospitalised Vaccinated and Unvaccinated Adults with COVID-19

Next Previous
Search
Trial Profile

A Phase 2, Double Blind Placebo-Controlled Study of BIT225, an Orally Administered SARS-CoV-2 Viroporin Inhibitor, to Evaluate Antiviral Activity, Safety, and Immune Biomarkers in Non-Hospitalised Vaccinated and Unvaccinated Adults with COVID-19

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BIT 225 (Primary)
  • Indications COVID 2019 infections
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 10 Aug 2023 According to a Biotron media release, company has commenced this trial and company has included a trial second site in Thailand.
    • 28 Jul 2023 According to Biotron media release,trial is currently underway at HIV-NAT, Thai Red Cross AIDS Research Centre Bangkok, and Khon Kaen University, Khon Kaen, Thailand.Enrolment into the study has progressed in a timely manner and is expected to be soon completed.
    • 28 Jul 2023 According to Biotron media release,Preliminary data is anticipated in the third quarter of 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top